Page 83 - 2019_02-Haematologica-web

NGS for genetic diagnosis of AML
leukemia using MiSeq: applicability for diag- nostics and disease monitoring. Haematologica. 2014;99(3):465–473.
29. Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translo- cation. Blood. 1991;77(9):2031–2036.
30. Yanagisawa K, Horiuchi T, Fujita S. Establishment and characterization of a new human leukemia cell line derived from M4E0. Blood. 1991;78(2):451–457.
31. Meissner R de V, Covas DT, Dias PMB, Job F, Leite M, Nardi NB. Analysis of mRNA transcripts in chronic myeloid leukemia patients. Genet Mol Biol. 1999;22:475–479.
32. Rücker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular character- ization. J Clin Oncol. 2006;24(24):3887– 3894.
33. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010;38(Database issue):D652–D657.
34. Katsanis SH, Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet. 2013;14(6):415–426.
35. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016;13 (1):3–11.
36. Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013;27(9):1820–1825.
37. Spencer DH, Abel HJ, Lockwood CM, et al. Detection of FLT3 internal tandem duplica- tion in targeted, short-read-length, next-gen- eration sequencing data. J Mol Diagn. 2013;15(1):81–93.
38. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17(1):120–124.
39. Frech M, Jehn LB, Stabla K, et al. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2017;102(4):e160-e162.
40. McKerrell T, Moreno T, Ponstingl H, et al. Development and validation of a compre- hensive genomic diagnostic tool for myeloid malignancies. Blood. 2016;128(1):e1-9.
41. Akagi T, Ogawa S, Dugas M, et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica. 2009;94(2):213–223.
42. Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A. 2009;106(31):12950–12955.
43. Gronseth CM, McElhone SE, Storer BE, et al.
Prognostic significance of acquired copy- neutral loss of heterozygosity in acute myeloid leukemia. Cancer. 2015;121(17): 2900–2908.
44. Wang H-Y, Rashidi HH. The new clinico- pathologic and molecular findings in myeloid neoplasms with inv(3)(q21q26)/ t(3;3)(q21;q26.2). Arch Pathol Lab Med. 2016;140(12):1404–1410.
45. Duncavage EJ, Abel HJ, Szankasi P, Kelley TW, Pfeifer JD. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol. 2012;25(6):795–804.
46. He J, Abdel-Wahab O, Nahas MK, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical set- ting. Blood. 2016;127(24):3004–3014.
47. Tyybakinoja A, Elonen E, Piippo K, Porkka K, Knuutila S. Oligonucleotide array-CGH reveals cryptic gene copy number alter- ations in karyotypically normal acute myeloid leukemia. Leukemia. 2007;21(3): 571–574.
48. Alvarez S, MacGrogan D, Calasanz MJ, Nimer SD, Jhanwar SC. Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization. Genes Chromosom Cancer. 2001;32(3):285–293.
49. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
haematologica | 2019; 104(2)
287